Gt biopharma reports first quarter 2021 results

Beverly hills, calif., may 17, 2021 /prnewswire/ -- gt biopharma, inc. ("gt biopharma" or the "company") (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager (trike™) protein biologic technology platform, today reported financial results for the first quarter ended march 31, 2021 and provided a general business update.
GTBP Ratings Summary
GTBP Quant Ranking